Retrospective study of alectinib treatment among variants of ALK fusion in lung adenocarcinoma [0.03%]
关于间变性淋巴瘤激酶不同融合类型肺腺癌患者的艾乐昔替尼治疗回顾性研究
Yuma Watanabe,Ayako Takigami,Shu Hisata et al.
Yuma Watanabe et al.
Background: Anaplastic lymphoma kinase (ALK) fusion genes are present in approximately 3-5% of non-small cell lung cancer (NSCLC) cases. Multiple echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) fusion vari...
MET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report [0.03%]
弥漫性胸膜间皮瘤中MET扩增与硫酸沙伏利替尼治疗的反应——一例报告
Yueying Chen,Mengyi Shen,Jiawen Lv et al.
Yueying Chen et al.
Background: Pleural mesothelioma (PM) is a rare malignancy globally, most frequently associated with alterations in tumor suppressor genes such as NF2, BAP1 and CDKN2A. In contrast, mutations or amplifications of the MET ...
Prognostic impact of thyroid transcription factor-1 expression and the efficacy of carboplatin plus (nab-) paclitaxel in non-squamous non-small cell lung cancer complicated with idiopathic interstitial pneumonias [0.03%]
甲状腺转录因子-1表达对非小细胞肺癌合并特发性间质性肺炎的预后影响及卡铂联合（白蛋白结合型）紫杉醇疗效分析
Yuto Terashima,Aya Fukuizumi,Koichiro Kamio et al.
Yuto Terashima et al.
Background: Previous studies have reported an association between expression of thyroid transcription factor 1 (TTF-1) and the efficacy of immune checkpoint inhibitors (ICIs), cytotoxic chemotherapy, and immunochemotherap...
A new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition [0.03%]
一种针对KRAS突变型非小细胞肺癌的新疗法：Exportin 1抑制剂的作用机制及其临床前景
Mitchell S von Itzstein,David E Gerber
Mitchell S von Itzstein
Neoadjuvant immunochemotherapy in potentially resectable small cell lung cancer: a real-world retrospective analysis [0.03%]
新辅助免疫化疗在潜在可切除的小细胞肺癌患者中的疗效分析：一项真实世界回顾性研究
Ting Wang,Kai-Li Huang,Dan Pu et al.
Ting Wang et al.
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options. Recent advancements in immunotherapy have shown promise in improving patient outcomes. However, the role of neoadjuvant...
Pathological complete response following neoadjuvant chemoimmunotherapy in cancer of unknown primary: a case report [0.03%]
化疗免疫新辅助治疗后原发灶不明癌症患者达到病理完全缓解的一例报告
Ying-Long Peng,Hong-Yi Zhu,Hui-Bing Gao
Ying-Long Peng
Background: Cancers of unknown primary (CUP) are a heterogeneous group of metastatic malignancies in which a primary tumor cannot be identified despite comprehensive diagnostic evaluation. Most CUP patients have a poor pr...
Real-world insights into multidisciplinary management and outcomes of stage III (N2-3) non-small cell lung cancer [0.03%]
关于分期III期（N2-3）非小细胞肺癌综合治疗的疗效和预后的现实世界数据见解
Jing-Sheng Cai,Jia-Qi Zhao,Dilimulati Abulizi et al.
Jing-Sheng Cai et al.
Background: Stage III (N2-3) non-small cell lung cancer (NSCLC) represents a highly heterogeneous group, with limited evidence to guide multidisciplinary management in real-world settings. This study aimed to evaluate tre...
Impact of baseline brain metastases on survival and CNS progression in NSCLC patients treated with immune checkpoint inhibitors in real-world studies: a systematic review and meta-analysis [0.03%]
基线脑转移对免疫检查点抑制剂真实世界研究中NSCLC患者生存和中枢神经系统进展的影响：系统评价和 Meta 分析
William J Shelton,Andrew P Mathews,Eric R Siegel et al.
William J Shelton et al.
Background: Brain metastases (BMs) are common in non-small cell lung cancer (NSCLC) and are associated with poor prognosis. Immune checkpoint inhibitors (ICIs) have improved survival outcomes in NSCLC, but their impact on...
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: efficacy and biomarker analysis of pemetrexed discontinuation [0.03%]
培美曲塞停药维持治疗转移性非鳞状非小细胞肺癌的疗效及生物标志物分析
Ying Lin,Ke Gong,Jingjing Wu et al.
Ying Lin et al.
Background: A standard first-line regimen for patients with driver-gene-negative metastatic non-squamous non-small cell lung cancer (nsqNSCLC) is immune checkpoint inhibitors (ICIs) combined with pemetrexed and platinum, ...
Current advances in mediastinal staging for non-small cell lung cancer: a narrative review [0.03%]
非小细胞肺癌纵隔分期的当前进展：综述
Fabrizio Minervini,Hannes Grünig,Peter Kestenholz et al.
Fabrizio Minervini et al.
Background and objective: Mediastinal staging, whether through non-surgical or surgical approaches, plays a pivotal role in the management of non-small cell lung cancer (NSCLC) due to its impact on therapeutic decision-ma...